| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Jupiter Neurosciences Inc. | JUNS101 | Friedreich’s Ataxia (FA) | Phase 2 | Intravenous | Genetic Disorder | |
| Jupiter Neurosciences Inc. | JUNS102 | Mucopolysaccharidosis type I | Phase 2 | Oral | Genetic Disorder | |
| Jupiter Neurosciences Inc. | JUNS108 | Early Alzheimer's Disease | Phase 2 | Intravenous | Neurology | |
| Jupiter Neurosciences Inc. | JOTROL - (JNS115) | Parkinson's disease | Phase 2a | Ongoing | Oral | Neurology |
| Jyong Biotech Ltd. | MCS-8 (PCP) | Urinary system diseases | Phase 2 | Ongoing | oral | N/A |
| Kairos Pharma Ltd. | Apalutamide and ENV105 (carotuximab) | Advanced metastatic castration-resistant prostate cancer | Phase 2 | Ongoing | oral intravenous | Oncology |
| Kairos Pharma Ltd. | ENV-105 | Prostate Cancer | Phase 2 | Data Released | Oral | Oncology |
| KALA BIO Inc. | KPI-012 - (CHASE) | Persistent corneal epithelial defect (PCED) | Phase 2b | Data Released | Topical ophthalmic | Opthalmic |